

85,000 CAPiTA participants

EQ-5D questionnaire for baseline measurement (October 2008 – January 2010)

With baseline EQ-5D score
and consent
~25,500 persons
= CHO-CAP baseline cohort

Without baseline EQ-5D score
~59,500 persons

**Develop CAP
(i.e. diseased persons)
'CAP cases'
~600 persons**

**Unaffected persons
(i.e. no CAP)
'controls'
~24,900 persons**

**Develop CAP
(i.e. diseased persons)
~1,400 persons**

**Unaffected persons
(i.e. no CAP)
~58,100 persons**

If consent, included in
diseased cohort.
Contact at 0, 1, 6 and
12 months

If consent, 2 controls
per CAP included in
non-diseased cohort,
by matching on:
•Age
•Sex
•Baseline EQ-5D score
Contact at 0, 1, 6 and
12 months.

Information on mortality, withdrawal, loss to follow-up and some information on socio-demographic data and comorbidity from main trial for all participants;

Information on hospital resources used from the Etio-CAP substudy and main trial CAP cases.